|
López-Castejón G, Pelegrín P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Investig Drugs. 2012 Jul;21(7):995-1007. doi: 10.1517/13543784.2012.690032. Epub 2012 May 22. Review. PubMed PMID: 22612568.
AÑO: 2012; IF: 4.744
|
22612568
|
Barberà-Cremades M, Baroja-Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrín P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1? release. FASEB J. 2012 Jul;26(7):2951-62. doi: 10.1096/fj.12-205765. Epub 2012 Apr 6. PubMed PMID: 22490780.
AÑO: 2012; IF: 5.704
|
|
Baroja-Mazo A, Pelegrín P. Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates. J Osteoporos. 2012;2012:408242. doi: 10.1155/2012/408242. Epub 2012 Jul 8. PubMed PMID: 22830074; PubMed Central PMCID: PMC3399340.
AÑO: 2012
|
|
Lopez-Castejón G, Baroja-Mazo A, Pelegrín P. Novel macrophage polarization model: from gene expression to identification of new anti-inflammatory molecules. Cell Mol Life Sci. 2011 Sep;68(18):3095-107. doi: 10.1007/s00018-010-0609-y. Epub 2010 Dec 28. PubMed PMID: 21188461.
AÑO: 2011; IF: 6.496
|
|
Jelassi B, Chantôme A, Alcaraz-Pérez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, Surprenant A, Roger S. P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011 May 5;30(18):2108-22. doi: 10.1038/onc.2010.593. Epub 2011 Jan 17. PubMed PMID: 21242969.
AÑO: 2011; IF: 6.373
|